Temporary Authorization for Use (ATU) to Avelumab for Treatment of Adult Patients With Metastatic Merkel Cell Carcinoma (mMCC)
Latest Information Update: 24 Nov 2021
At a glance
- Drugs Avelumab (Primary)
- Indications Merkel cell carcinoma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Merck KGaA
- 24 Nov 2021 Results (n=150 ; data cutoff: 22 Mar 2021) assessing safety and efficacy from patients enrolled in EAP in Europe and the Middle East published in the International Journal of Cancer
- 01 Apr 2021 Results (n=46; data cut-off date between January 2016 and 24 July 2018) assessing a real-world experience with avelumab as a second-line treatment in a subset of Latin America (LATAM) participants enrolled in a global expanded access program for patients with metastatic merkel cell carcinoma, published in the Cancer Immunology, Immunotherapy.
- 07 Oct 2019 Status changed from recruiting to completed.